SCHEMBL275880

SCHEMBL275880

CC(C)(C)N(C(=O)O)C1CCC(N)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL870791 1.00
SCHEMBL275879 1.00
Hydrochloric Acid SCHEMBL4885672 0.98
SCHEMBL527479 0.89 DPP4 (0.30)
SCHEMBL15772895 0.89
SCHEMBL1700023 0.89
SCHEMBL15772898 0.89
SCHEMBL15772897 0.89
SCHEMBL19409076 0.89
Hydrochloric Acid SCHEMBL1442521 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545685-B2 Dispiropyrrolidine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-02-10 US disclosed
EP-4682148-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2026-01-21 EP disclosed
US-20250161318-A1 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT ABBVIE INC (US) 2025-05-22 US disclosed
US-12251387-B2 Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-03-18 US disclosed
US-20250019369-A1 N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors Cerevance, Inc. (US) 2025-01-16 US disclosed
US-20250019364-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2025-01-16 US disclosed
US-20240425517-A1 NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION PRAZER THERAPEUTICS INC. (KR) 2024-12-26 US disclosed
EP-4474383-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2024-12-11 EP disclosed
EP-3740479-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2024-11-20 EP disclosed
EP-4450490-A1 NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION Prazer Therapeutics Inc. (KR) 2024-10-23 EP disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed
EP-2114945-A1 PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-11-11 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090131446-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases GALAPAGOS, N.V. (BE) 2009-05-21 US disclosed
US-20080214581-A1 Purine Derivatives as Agonists of the Adenosine A2a Receptor GLAXO GROUP LIMITED (GB) 2008-09-04 US disclosed
WO-2008092831-A1 PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-07 WO disclosed
EP-1953163-A1 Pteridinone derivatives as PI3-kinases inhibitors Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2008-08-06 EP disclosed
US-20070078131-A1 Thieno-pyridinone derivatives as kinase inhibitors CELLTECH R&D LIMITED (GB) 2007-04-05 US disclosed
US-7132435-B2 Syn-1H-indazole-3-carboxylic acid (4-{[2-(2,3-dihydro-benzo[b]thiophen-6-yloxy)-5-fluoro-pyridine-3-carbonyl]amino}-cyclohexyl)-amide; useful as cyclic nucleotide phosphodiesterase-4 ( PDE-4 ) inhibitor PFIZER INC. (US) 2006-11-07 US disclosed
US-20050020639-A1 Novel compounds PFIZER INC 2005-01-27 US disclosed